SHP2 Inhibitor ET0038 Monotherapy in Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
This is a Phase I, open-label, multi-center, dose-finding study to assess the safety,
pharmacokinetics, and preliminary efficacy of ET0038 in patients with advanced solid tumors.
It is anticipated that approximately 34 subjects will be enrolled in the dose-escalation
phase of the study. ET0038 will be administered orally once daily (QD) in 21-day treatment
cycles.